Our latest detailed adjuvant SERDs analsyis reveals a potential mispricing emerging between Roche and AstraZeneca, with the market potentially extrapolating lidERA into a broader commercial opportunity than is warranted, while underappreciating more practice-aligned pathways elsewhere. The core debate is whether investors should be underwriting a broad SERD backbone in early breast cancer today, or positioning for a narrower outcome with a different catalyst path into 2027 that could shift relative value across the group.